NCI 8628 - A Randomized Phase II Study of Ziv-aflibercept and High Dose Interleukin-2 (HD IL-2) or HD IL-2 Alone for Inoperable Stage III or IV Melanoma

BACKGROUND: Interleukin-2 (IL2) is a growth factor for T and NK cells, promotes pro-inflammatory cytokines and can lead to durable responses in melanoma. VEGF promotes angiogenesis and modulates host innate and adaptive immunity. High VEGF levels were associated with nonresponse to IL2. Ziv- afliber...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Tarhini, Ahmad A., Frankel, Paul, Ruel, Christopher, Ernstoff, Marc S., Kuzel, Timothy M., Logan, Theodore F., Khushalani, Nikhil I., Tawbi, Hussein A., Margolin, Kim A., Awasthi, Sanjay, Butterfield, Lisa H., McDermott, David, Chen, Alice, Lara, Primo N., Kirkwood, John M.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6504933/
https://ncbi.nlm.nih.gov/pubmed/30303516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31734
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars